DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS

The authors of this review and meta-analysis of phase III trials evaluated the use of daratumumab for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. While the individual trials did not demonstrate a statistically significant survival benefit, the meta-analysis did showed improvement in both progression-free and overall survival with daratumumab for both standard-risk and …

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS Read More »